Literature DB >> 24657156

The crystal structure of MPK38 in complex with OTSSP167, an orally administrative MELK selective inhibitor.

Yong-Soon Cho1, Yingjin Kang1, Kuglae Kim1, Young-Je Cha1, Hyun-Soo Cho2.   

Abstract

Murine protein serine/threonine kinase 38 (MPK38), also known as maternal embryonic leucine zipper kinase (MELK), has been associated with various human cancers and plays an important role in the formation of cancer stem cells. OTSSP167, a MELK selective inhibitor, exhibits a strong in vitro activity, conferring an IC50 of 0.41nM and in vivo effect on various human cancer xenograft models. Here, we report the crystal structure of MPK38 (T167E), an active mutant, in complex with OTSSP167 and describe its detailed protein-inhibitor interactions. Comparison with the previous determined structure of MELK bound to the nanomolar inhibitors shows that OTSSP167 effectively fits into the active site, thus offering an opportunity for structure-based development and optimization of MELK inhibitors.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Inhibitors; MELK; MPK38; OTSSP167

Mesh:

Substances:

Year:  2014        PMID: 24657156     DOI: 10.1016/j.bbrc.2014.03.034

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  15 in total

Review 1.  Exploiting replicative stress to treat cancer.

Authors:  Matthias Dobbelstein; Claus Storgaard Sørensen
Journal:  Nat Rev Drug Discov       Date:  2015-05-08       Impact factor: 84.694

2.  Mutant P53 induces MELK expression by release of wild-type P53-dependent suppression of FOXM1.

Authors:  Lakshmi Reddy Bollu; Jonathan Shepherd; Dekuang Zhao; Yanxia Ma; William Tahaney; Corey Speers; Abhijit Mazumdar; Gordon B Mills; Powel H Brown
Journal:  NPJ Breast Cancer       Date:  2020-01-03

Review 3.  Resistance to Cell Death and Its Modulation in Cancer Stem Cells.

Authors:  Ahmad R Safa
Journal:  Crit Rev Oncog       Date:  2016

4.  Glioblastoma stem cells (GSCs) epigenetic plasticity and interconversion between differentiated non-GSCs and GSCs.

Authors:  Ahmad R Safa; Mohammad Reza Saadatzadeh; Aaron A Cohen-Gadol; Karen E Pollok; Khadijeh Bijangi-Vishehsaraei
Journal:  Genes Dis       Date:  2015-06

5.  Genome and transcriptome delineation of two major oncogenic pathways governing invasive ductal breast cancer development.

Authors:  Luay Aswad; Surya Pavan Yenamandra; Ghim Siong Ow; Oleg Grinchuk; Anna V Ivshina; Vladimir A Kuznetsov
Journal:  Oncotarget       Date:  2015-11-03

6.  MELK is not necessary for the proliferation of basal-like breast cancer cells.

Authors:  Hai-Tsang Huang; Hyuk-Soo Seo; Tinghu Zhang; Yubao Wang; Baishan Jiang; Qing Li; Dennis L Buckley; Behnam Nabet; Justin M Roberts; Joshiawa Paulk; Shiva Dastjerdi; Georg E Winter; Hilary McLauchlan; Jennifer Moran; James E Bradner; Michael J Eck; Sirano Dhe-Paganon; Jean J Zhao; Nathanael S Gray
Journal:  Elife       Date:  2017-09-19       Impact factor: 8.140

7.  CRISPR/Cas9 mutagenesis invalidates a putative cancer dependency targeted in on-going clinical trials.

Authors:  Ann Lin; Christopher J Giuliano; Nicole M Sayles; Jason M Sheltzer
Journal:  Elife       Date:  2017-03-24       Impact factor: 8.140

Review 8.  Targeting DNA Replication Stress for Cancer Therapy.

Authors:  Jun Zhang; Qun Dai; Dongkyoo Park; Xingming Deng
Journal:  Genes (Basel)       Date:  2016-08-19       Impact factor: 4.096

9.  MELK is a novel therapeutic target in high-risk neuroblastoma.

Authors:  Shan Guan; Jiaxiong Lu; Yanling Zhao; Yang Yu; Hui Li; Zhenghu Chen; Zhongcheng Shi; Haoqian Liang; Mopei Wang; Kevin Guo; Xiangmei Chen; Wenjing Sun; Shayahati Bieerkehazhi; Xin Xu; Surong Sun; Saurabh Agarwal; Jianhua Yang
Journal:  Oncotarget       Date:  2017-12-20

10.  Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer.

Authors:  Corey Speers; Shuang G Zhao; Vishal Kothari; Alyssa Santola; Meilan Liu; Kari Wilder-Romans; Joseph Evans; Nidhi Batra; Harry Bartelink; Daniel F Hayes; Theodore S Lawrence; Powel H Brown; Lori J Pierce; Felix Y Feng
Journal:  Clin Cancer Res       Date:  2016-05-25       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.